|
Market Cap (18-May) $18,907,918 (738th) |
Close (30-Jun) $0.160 |
Volume (30-Jun) 68,980 |
Shortsold (1-Nov) 1 (0.00%) (657th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.11 |
KZA released this announcement to the ASX on 21 June 2021, 14:45. The announcement is not marked as price sensitive, and is 3 page(s) in length and 1.04MB in size.
You can view all announcements from KZA and see how they appear on a price chart on the announcements page.
At the date of this announcement, KZA was 0.001% short sold according to ASIC data. It was ranked the 655th most shorted stock on the ASX. It remains ranked 657th as of the latest reported data (01 November 2023).
| Other Recent Announcements from KZA | |
|---|---|
| Kazia Corporate Update and Corporate Presentation | 26 June 2023, 9:17 |
| Launch of LUMOS2 Study | 8 June 2023, 8:23 |
| Constitution | 7 June 2023, 14:05 |
| Ceasing to be a substantial holder | 21 June 2021, 14:45 |
| Kazia launches new paxalisib phase II clinical trial | 15 June 2021, 9:08 |
| Kazia paxilisib in Dana Farber study enrols first patient | 7 June 2021, 9:40 |
| Appendix 3Y for 3 directors | 2 June 2021, 14:59 |
You must be logged in to post a reply.
